#Denmark #Copenhagen #dermatology #TOOsonix #MikronMed

TOOsonix and MikronMed Join Forces to Revolutionize Dermatological Care in the Nordic Region

COPENHAGEN, Denmark - In a significant development for skin health, TOOsonix A/S, a leader in the use of high-intensity focused ultrasound technology, has initiated a vital partnership with MikronMed AB, a premier medical equipment distributor in the Nordics. This collaboration is set to introduce cutting-edge dermatological treatments to the 27 million inhabitants of the Nordic region, ensuring prompt and efficient care for prevalent skin conditions, notably non-melanoma skin cancers.

Enhancing Access to Innovative Treatments

TOOsonix's innovative systems, which have received MDR CE marking, are at the forefront of medical technology in dermatology. By collaborating with MikronMed, TOOsonix aims to enhance accessibility to its advanced treatment options across healthcare facilities in Sweden, Norway, Denmark, Finland, and Iceland. The partnership promises to make non-invasive treatments available rapidly, often requiring less than 90 seconds per procedure.

Meeting Demands of a Growing Dermatology Market

As the Nordic population ages, with projections indicating that by 2035, about 20% will be over the age of 70, there is an escalating need for effective skin care solutions. Skin cancers and age-related conditions are becoming increasingly prevalent, making this partnership timely.

MikronMed's CEO, Christer Persson, emphasized the transformative potential of this collaboration: “The Nordic dermatology market is evolving, and the introduction of TOOsonix’s breakthrough technology will enhance care delivery for both clinicians and patients.” He also highlighted the unique expertise MikronMed brings to the table to promote the use of these advanced systems in the region.

The Power of Focused Ultrasound Technology

The TOOsonix system ONE-M operates as a Class IIa medical device employing focused ultrasound specifically targeting dermatological issues. This technology presents various advantages, including the effective treatment of pre-cancers, intradermal tumors, and other medical or aesthetic skin conditions without the need for anesthetics or recovery downtime. This stands in sharp contrast to traditional methods, which may involve more invasive procedures and longer recovery times.

A Shared Vision for the Future

Tomasz Zawada and Torsten Bove, the founders of TOOsonix, conveyed their excitement about this strategic partnership stating, “We believe in making our focused ultrasound therapy more accessible, addressing the long-standing challenges faced by patients in obtaining timely care.” Their vision extends beyond immediate collaboration, aiming for longer-term enhancements in the field of dermatology.

Consolidated Holdings A/S’s CEO, Lone Kunoee, supports this vision, indicating that this collaboration is just the first step toward revolutionizing dermatological care in the region. Kunoee stated, “This partnership reflects a larger agenda to redefine therapeutic options for patients in need.”

A Promising Future for Nordic Dermatology

As TOOsonix and MikronMed embark on this journey together, the partnership symbolizes a significant advance in addressing the urgent demands of dermatological care in the Nordic region. The focus on non-invasive treatment technology holds promise not just for improved health outcomes but also for enhancing the quality of life for many individuals facing skin health challenges. The future of dermatology in the Nordics looks bright as both companies work to deliver innovative treatments that could revolutionize patient experiences in skin care.

For further details about TOOsonix and its innovative treatments or the role of MikronMed in distributing these technologies, please visit their respective websites: TOOsonix and MikronMed.